Skip to main content

Abstract

The probiotic preparation Lacidofil® has been commercially available in Europe, Asia and North America since 1995. This product is a combination of two strains, Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. The strains have been evaluated for safety, identity and mechanisms of probiotic action in vitro, in animal models and human clinical trials. The strains adhered to human epithelial cells, helped to maintain the barrier function and blocked the adhesion of a number of pathogens, allowing them to be cleared from the intestine. The strains also elicited an anti-inflammatory response by down-regulating IL-1β, IL-8 and TNF-α. In various stress models, the probiotic combination facilitated better coping and outcomes which may be through the maintenance of barrier function and suppressing inflammation. Overall, pre-clinical studies suggest a potential anti-infectious role for the strains and the combination. Clinical studies, primarily in children, have identified Lacidofil as an effective supplement for various gastrointestinal diseases such as antibiotic-associated diarrhoea and acute gastroenteritis. Recent research has also indicated that Lacidofil may be beneficial for individuals with atopic dermatitis or vaginal dysbacteriosis.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lacticaseibacillus rhamnosus R0011Improved Atopic DermatitisBeneficial
Moderate
Lacticaseibacillus rhamnosus R0011Improved Stress ManagementBeneficial
Moderate
Lacticaseibacillus rhamnosus R0011Improved Vaginal DysbacteriosisBeneficial
Moderate
Lacticaseibacillus rhamnosus R0011Reduced Gastrointestinal Disease SymptomsBeneficial
Large
Lacticaseibacillus rhamnosus R0011Reduced Gastrointestinal Pathogen AdhesionBeneficial
Moderate
Lacticaseibacillus rhamnosus R0011Reduced Inflammatory ResponseBeneficial
Large
Lactobacillus helveticus R0052Enhanced Resistance to InfectionsBeneficial
Moderate
Lactobacillus helveticus R0052Improved Atopic DermatitisBeneficial
Moderate
Lactobacillus helveticus R0052Improved Coping StrategiesBeneficial
Moderate
Lactobacillus helveticus R0052Improved Gastrointestinal HealthBeneficial
Large
Lactobacillus helveticus R0052Maintained Barrier FunctionBeneficial
Moderate
Lactobacillus helveticus R0052Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus helveticus Rosell-52Improved Atopic Dermatitis SymptomsBeneficial
Moderate
Lactobacillus helveticus Rosell-52Improved Barrier FunctionBeneficial
Moderate
Lactobacillus helveticus Rosell-52Improved Vaginal HealthBeneficial
Moderate
Lactobacillus helveticus Rosell-52Reduced Gastrointestinal Disease Incidence in ChildrenBeneficial
Large
Lactobacillus helveticus Rosell-52Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus rhamnosus R0011Improved Coping StrategiesBeneficial
Moderate
Lactobacillus rhamnosus R0011Improved Gastrointestinal HealthBeneficial
Large
Lactobacillus rhamnosus R0011Improved Skin HealthBeneficial
Moderate
Lactobacillus rhamnosus R0011Improved Vaginal HealthBeneficial
Moderate
Lactobacillus rhamnosus R0011Reduced Inflammatory ResponseBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.